Premium
Actions of locally administered adrenoceptor agonists on histamine‐induced cutaneous responses in atopic eczema
Author(s) -
ARCHER C.B.,
PAUL W.,
MORLEY J.,
MACDONALD D.M.
Publication year - 1984
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1111/j.1365-2230.1984.tb00816.x
Subject(s) - medicine , classics , dermatology , history
Summary An in vivo method for the assessment of adrenergic reactivity has been employed to examine alpha‐adrenergic and beta‐adrenergic responses in atopic eczema. In a randomised, double‐blind study, intradermal administration of noradrenaline (predominantly an alpha‐1‐adrenoceptor agonist) or salbutamol (predominantly a beta‐2‐adrenoceptor agonist) significantly inhibited the histamine wheal response ( P <0.001) in atopic and control subjects. However, the responses to alpha‐adrenergic or beta‐adrenergic effects were similar in both groups, a finding which does not support the concept that atopy is due to impaired beta‐adrenergic reactivity accompanied by enhanced alpha‐adrenergic reactivity. The ability of patients with atopic eczema to respond normally to the anti‐inflammatory effect of a beta‐2‐adrenoceptor agonist is of therapeutic interest.